Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment-Reference-Cited by-同舟云学术

Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment

Published:2024-05-14 Issue:7 Volume:56 Page:575-580
ISSN:2374-4235
Container-title:Infectious Diseases
language:en
Short-container-title:Infectious Diseases

Author:

Aguareles Jose¹²³,Villares Fernández Paula⁴,Forné Carles⁵⁶,Martí-Ballesteros Eva María²⁷,Pradillo Fernández Virginia²⁷,Sotres-Fernandez Gabriel¹²,de la Fuente-Burguera Adolfo⁸,Navarro-San Francisco Carolina⁹,Buzón-Martín Luis Miguel⁹,García-Delangue Teresa¹⁰,Aiello Francesco Tommaso¹¹,Carnevali-Ruiz Daniel¹²,Lloris Raquel¹²,Luepke-Estefan Xavier Erik¹³,López-Martín José Antonio¹²,Jimeno José María¹²,García-Casas Ana¹³,Guisado-Vasco Pablo¹²

Affiliation:

1. Internal Medicine Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain

2. Facultad de Ciencias Biomédicas y de la Salud, Medicine Department, Universidad Europea de Madrid, Madrid, Spain

3. Research and Clinical Trials Unit, Hospital Universitario Quirónsalud Madrid, Madrid, Spain

4. Internal Medicine Department, Hospital Universitario HM Sanchinarro, Madrid, Spain

5. Heorfy Consulting, Lleida, Spain

6. Basic Medical Sciences Department, University of Lleida, Lleida, Spain

7. Haematology Department, Hospital Universitario Quirónsalud Madrid, Madrid, Spain

8. Haematology and Haemotherapy Service, MD Anderson Cancer Center, Madrid, Spain

9. Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario de Burgos, Burgos, Spain

10. Internal Medicine Department, Hospital HLA Universitario Moncloa, Madrid, Spain

11. Internal Medicine Department, Hospital Clinic de Barcelona, Barcelona, Spain

12. VirologyUnit, PharmaMar S.A., Madrid, Spain

13. Coordinator of Compassionate Drug Use, PharmaMar S.A., Madrid, Spain

Funder

PharmaMar S.A. (Colmenar Viejo, Spain) and Hospital Universitario QuironSalud Madrid

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/23744235.2024.2351043

Reference8 articles.

1. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore

2. Deaths Due to COVID-19 in Patients With Cancer During Different Waves of the Pandemic in the US

3. Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant

4. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies

5. Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses